Loading...

MIST MILESTONE PHARMACEUTICALS INC Product Launches 8-K Filing

MLST

MST

MILESTONE PHARMACEUTICALS INC

(MIST)

2026 8-K

Financial Results

Financial Results

Royalty Interest Sale

Marketing Approval Update

FDA Approval Announcement

Financial Results Update

Equity Offerings

Contract Renewal

Pre-Market Approval

Financial Statements

Shareholder Meeting

Share Sale Agreement

Financial Results

Corporate Presentation

Q3 Financial Results

Board Appointment

Financial Results Announcement

Cooperation Agreement with ...

Financial Results Announcement

Financial Results Announcement

Underwriting Agreement for ...

FDA Refusal to File Letter

Financial Results Announcement

Other Special Situation

NDA Submission for Etripami...

Financial Results and Update

Annual Meeting of Shareholders

Financial Results Announcement

Creation of Financial Oblig...

Financial Results Announcement

Purchase and Sale Agreement...

Management Changes

Regulation FD Disclosure

Corporate Presentation

External Links:

On January 26, 2026, Milestone Pharmaceuticals Inc. announced the release of CARDAMYST (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in the US.

AI Assistant

MILESTONE PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.